Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22777505 | 0.94 | CHRM1 (0.48) | SCN9ACHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL22373838 | 0.93 | SCN9A (0.48) | SCN9ACHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL23920500 | 0.87 | CHRM1 (0.54) | SCN9ACHRM1CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL22362258 | 0.83 | SCN9A (0.42) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL21050218 | 0.81 | SCN9A (0.56) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL22362359 | 0.80 | ADAMTS4 (0.45) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL22373840 | 0.76 | ATF4 (0.44) | SCN9A | |
| Trifluoroacetic Acid SCHEMBL21819270 | 0.75 | ATF4 (0.50) | SCN9ACNR2 | |
| Trifluoroacetic Acid SCHEMBL22777264 | 0.74 | ATF4 (0.48) | SCN9A | |
| SCHEMBL22373871 | 0.74 | HTT (0.41) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930697-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-113840597-A | Integrated stress response pathway inhibitors | 普拉西斯生物技术有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20200270232-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270232-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | SCN9A 4611/4885CHRM1 4819/4885CHRM3 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.